Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 3
2007 1
2008 4
2009 5
2010 5
2011 9
2012 4
2013 5
2014 8
2015 13
2016 10
2017 15
2018 8
2019 17
2020 26
2021 23
2022 21
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31142246

170 results

Results by year

Filters applied: . Clear all
Page 1
Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.
Lee GW, Go SI, Kim SH, Hong J, Kim YR, Oh S, Kim SY, Do YR, Lee H, Lee SI, Bae SH, Oh SY, Song MK, Lee WS, Lee B, Kim JS, Kim MK, Kang HJ, Ahn JS, Yhim HY, Kim HJ, Kim SJ, Kim WS, Suh C; Consortium for Improving Survival of Lymphoma (CISL) study group. Lee GW, et al. Leuk Lymphoma. 2015 Apr;56(4):1020-6. doi: 10.3109/10428194.2014.946027. Epub 2014 Aug 20. Leuk Lymphoma. 2015. PMID: 25039351
Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.
Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS. Chen YB, et al. Leuk Lymphoma. 2010 May;51(5):789-96. doi: 10.3109/10428191003699852. Leuk Lymphoma. 2010. PMID: 20367136
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE. Johnston PB, et al. Lancet Haematol. 2016 Jul;3(7):e309-16. doi: 10.1016/S2352-3026(16)30040-0. Epub 2016 Jun 5. Lancet Haematol. 2016. PMID: 27374464 Free PMC article. Clinical Trial.
170 results